Answers are grounded in this paper and cite their sources.
UL16-binding protein 2 (ULBP2) is a stress-inducible ligand of natural killer group 2 member D (NKG2D) that connects cellular stress to immune surveillance. Its consequences in cancer depend on membrane accessibility, ligand density, proteolytic shedding, soluble-ligand exposure, duration of stimulation, and effector-cell fitness rather than bulk expression alone. Accessible membrane ULBP2 can support NKG2D–DAP10-dependent natural killer (NK) cell cytotoxicity and CD8 + T-cell costimulation, whereas shedding reduces cell-surface ligand and can generate soluble ULBP2 (sULBP2). Chronic surface-ligand exposure has been associated with NKG2D adaptation in heterologous mouse models; direct human in-vivo validation and quantitative exposure thresholds remain unavailable. In clinical cohorts, associations between circulating sULBP2 and prognosis do not establish that sULBP2 itself mediates immunosuppression. This review distinguishes ULBP2-specific observations from pan-NKG2D-ligand findings and platform-based extrapolations. It critically evaluates molecular regulation, immune activation and escape, biomarker assays, and CAR-based therapies, multispecific engagers, antibodies, and antibody–drug conjugates (ADCs). EVOLVE104 recognizes ULBP2/5/6 and is under phase I investigation, but the available public sources contain no mature clinical efficacy or safety outcomes; ULBP2-specific CAR-T approaches remain preclinical and ULBP2-directed ADCs lack target-developability validation. Translation will require matched measurements of surface ULBP2 and sULBP2, human-relevant normal-tissue testing, functional immune readouts, and construct-specific assessment of target selectivity, internalization, and exposure.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: